Year in Review #ACR22
Pre-expos PPx for COVID!
Tix-Cil (Evusheld): risk reduction 77%
Cardiac AES 0.6% vs placebo 0.2%
Only 3.3% were on immunosuppression
But Israeli study with immunosuppressed:
92% half as likely to be hospitalized or die
1/2 less infections
@RheumNow
Links:
13-11-2022